BRIEF—BioMarin wins Chinese approval for Vimizim

BioMarin has won Chinese approval for Vimizim (elosulfase alfa) to treat people with the rare disease mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.

In May 2018, the Chinese government issued the country's first national list of rare diseases, which included MPS. Vimizim is the first treatment in China approved for this condition.

Chief executive Jean-Jacques Bienaimé said: "We hope to continue to deliver therapies to treat patients who have rare genetic diseases with unmet medical needs.”